Richard Ramko is a partner in Ernst & Young's South Florida practice, primarily serving publicly-held and emerging growth companies in the Health Sciences, Biotech and Technology industries.
Ramko has extensive experience serving large, publicly-held companies as well as newly formed start-ups and venture-backed enterprises. Richard has 15 years of experience, including 13 years in public accounting and 2 years in executive level financial positions in private industry and is a certified public accountant in Florida and Tennessee. Some of his current clients include Andrx Corporation, Nabi Biopharmaceuticals, Stiefel Laboratories and SFBC International.
This table primarily, the reason we put this one in here is to show R&D expense or percentage of revenue, clearly biotech is spending more than big pharma; however, in sheer dollars big pharma continues to spend huge amounts but as a ratio of market capitalization to revenue, the biotech companies a...(Full transcript available to logged in subscribers.).
Register & Subscribe
Login
